Exploring WRN Inhibition in MSI Tumors to Expand Synthetic Lethality Strategies Beyond PARP
• See how the MD Anderson Cancer Center is advancing first-in-human trial data for WRN inhibitors in MSI solid tumors
• Interpreting translational relevance and biomarker integration
• Positioning WRN as a synthetic lethality target beyond PARP